JP2006506367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006506367A5 JP2006506367A5 JP2004544577A JP2004544577A JP2006506367A5 JP 2006506367 A5 JP2006506367 A5 JP 2006506367A5 JP 2004544577 A JP2004544577 A JP 2004544577A JP 2004544577 A JP2004544577 A JP 2004544577A JP 2006506367 A5 JP2006506367 A5 JP 2006506367A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- peptide
- ppi
- bioadhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000000227 bioadhesive Substances 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 6
- 230000027119 gastric acid secretion Effects 0.000 claims 6
- 210000002784 stomach Anatomy 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical group C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 claims 5
- 108010079943 Pentagastrin Proteins 0.000 claims 4
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims 4
- 208000000718 duodenal ulcer Diseases 0.000 claims 4
- 201000000052 gastrinoma Diseases 0.000 claims 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 4
- -1 isomeprazole Chemical compound 0.000 claims 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 4
- 230000007170 pathology Effects 0.000 claims 4
- 229960000444 pentagastrin Drugs 0.000 claims 4
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 claims 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 206010019375 Helicobacter infections Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 206010042220 Stress ulcer Diseases 0.000 claims 2
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 2
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 claims 2
- 201000011032 Werner Syndrome Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 150000001447 alkali salts Chemical class 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002183 duodenal effect Effects 0.000 claims 2
- 201000006549 dyspepsia Diseases 0.000 claims 2
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 2
- 201000005917 gastric ulcer Diseases 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 229960003174 lansoprazole Drugs 0.000 claims 2
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims 2
- 229950007395 leminoprazole Drugs 0.000 claims 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- 229960000381 omeprazole Drugs 0.000 claims 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 2
- 229960005019 pantoprazole Drugs 0.000 claims 2
- 208000000689 peptic esophagitis Diseases 0.000 claims 2
- 229940126409 proton pump inhibitor Drugs 0.000 claims 2
- 239000000612 proton pump inhibitor Substances 0.000 claims 2
- 229960004157 rabeprazole Drugs 0.000 claims 2
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims 2
- 238000010992 reflux Methods 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- ARCGXLSVLAOJQL-UHFFFAOYSA-N trimellitic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(C(O)=O)=C1 ARCGXLSVLAOJQL-UHFFFAOYSA-N 0.000 claims 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- NBKZGRPRTQELKX-UHFFFAOYSA-N (2-methylpropan-2-yl)oxymethanone Chemical compound CC(C)(C)O[C]=O NBKZGRPRTQELKX-UHFFFAOYSA-N 0.000 claims 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL15228902A IL152289A0 (en) | 2002-10-14 | 2002-10-14 | Method and composition for inhibiting h.pylori infection in a mammalian tissue |
| PCT/IB2003/004453 WO2004034957A2 (en) | 2002-10-14 | 2003-10-09 | Methods for treatment of helicobacter pylori-associated disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006506367A JP2006506367A (ja) | 2006-02-23 |
| JP2006506367A5 true JP2006506367A5 (enExample) | 2006-11-24 |
Family
ID=29765063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004544577A Pending JP2006506367A (ja) | 2002-10-14 | 2003-10-09 | ヘリコバクター・ピロリ関連疾患の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7271146B2 (enExample) |
| EP (1) | EP1567181A4 (enExample) |
| JP (1) | JP2006506367A (enExample) |
| AU (1) | AU2003274392A1 (enExample) |
| CA (1) | CA2503325A1 (enExample) |
| IL (1) | IL152289A0 (enExample) |
| WO (1) | WO2004034957A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007503427A (ja) * | 2003-08-27 | 2007-02-22 | ベクタ・リミテッド | 胃酸分泌の抑制を必要とする病状を治療するための組成物 |
| WO2005027955A1 (en) * | 2003-09-24 | 2005-03-31 | Vecta Ltd. | Oral compositions for the stimulation of gastric acid secretion comprising pentagastrin |
| US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| US7803817B2 (en) * | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| AU2007278986B2 (en) * | 2006-07-25 | 2010-09-16 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI |
| WO2009040006A1 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Spantide for therapeutic uses |
| US20110046079A1 (en) * | 2008-01-16 | 2011-02-24 | Mullin James M | Use of Proton Pump Inhibitors as Drug Delivery Adjuvants |
| EP2601947A1 (en) | 2011-12-05 | 2013-06-12 | Abo Bakr Mohammed Ali Al-Mehdar | Fixed-dose combination for treatment of helicobacter pylori associated diseases |
| US9700514B1 (en) | 2014-08-20 | 2017-07-11 | Darren Rubin | Single solid oral dosage forms for treating Helicobacter pylori infection and duodenal ulcer disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4891356A (en) | 1987-07-15 | 1990-01-02 | Brigham & Women's Hospital | Proteinase inhibitors for treatment of gastrointestinal ulcer disease |
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| CA2331834A1 (en) | 1998-06-18 | 1999-12-23 | Michal Y. Chowers | Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders |
| US7365047B1 (en) * | 1999-09-28 | 2008-04-29 | The Regents Of The University Of California | Use of pentagastrin to inhibit gastric acid secretion or as a diuretic |
| FR2832311B1 (fr) * | 2001-11-21 | 2004-04-16 | Besins Int Belgique | Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations |
-
2002
- 2002-10-14 IL IL15228902A patent/IL152289A0/xx unknown
-
2003
- 2003-10-09 AU AU2003274392A patent/AU2003274392A1/en not_active Abandoned
- 2003-10-09 JP JP2004544577A patent/JP2006506367A/ja active Pending
- 2003-10-09 WO PCT/IB2003/004453 patent/WO2004034957A2/en not_active Ceased
- 2003-10-09 EP EP03758376A patent/EP1567181A4/en not_active Withdrawn
- 2003-10-09 CA CA002503325A patent/CA2503325A1/en not_active Abandoned
- 2003-10-14 US US10/682,937 patent/US7271146B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2529984C (en) | Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors | |
| JP4293750B2 (ja) | ベンズイミダゾール誘導体を含む経口投与製剤及びその製造方法 | |
| RU2166935C2 (ru) | Таблетированная многоединичная лекарственная форма, способ ее получения, способ ингибирования секреции желудочной кислоты или лечения желудочно-кишечных заболеваний у млекопитающих и человека | |
| JP5162689B2 (ja) | 活性成分としてのパントプラゾールを含有する投与形 | |
| JP2008534438A5 (enExample) | ||
| JP2004508396A (ja) | 非ステロイド性抗炎症薬およびプロトンポンプ阻害薬を含有する医薬製剤 | |
| JP2006506367A5 (enExample) | ||
| ES2376466T3 (es) | Forma de dosificación farmacéutica que comprende peletes, as�? como su procedimiento de fabricación. | |
| CA2605839A1 (en) | Stabilized composition of a proton pump inhibitor | |
| KR20120104991A (ko) | 약학적 고체 제형 | |
| WO2007074910A1 (ja) | 放出制御固形製剤 | |
| JP5474541B2 (ja) | 小さいジカルボン酸の誘導体と組み合わせてｐｐｉを用いる胃酸分泌を阻害する組成物および方法 | |
| JP2014240435A (ja) | 胃酸分泌を阻害するための組成物および方法 | |
| JP4800926B2 (ja) | 活性成分としての（ｓ）−パントプラゾールを含有する医薬組成物 | |
| CA2740974A1 (en) | Dosage forms for the rapid and sustained elevation of gastric ph | |
| ES2466441T3 (es) | Composiciones farmacéuticas que comprenden fármaco antiinflamatorio no esteroideo, acetaminofén e inhibidor de la bomba de protones | |
| JP2006513239A5 (enExample) | ||
| CN100488507C (zh) | 含有泮托拉唑作为活性成分的剂型 | |
| RU2414889C2 (ru) | Фармацевтическая композиция для лечения язвы желудка и двенадцатиперстной кишки в форме твердых желатиновых капсул, содержащая рабепразол или его производные, и способ ее получения | |
| CN100457104C (zh) | 质子泵抑制剂的碱性盐 | |
| TR201605487A1 (tr) | Anti̇ülserati̇f farmasöti̇k terki̇pler | |
| TR201503285A2 (tr) | Anti̇ülserati̇f farmasöti̇k terki̇pler |